In India, 2 drugs that are currently losing weight and controlling diabetes have been formally launched. These include Ali Lily’s Maunjaro and Novo Nordisk’s Vegovi. Medicines like Ozapic, Maunjaro and Vagovi are present in many countries around the world, but now it is reported that Eli Lily and Novo Nordisk Company is soon going to launch in the market for the treatment of obesity. Prices of these weight loss pills in America will be equal to their weight loss injections. However, both companies have not yet disclosed the prices of these drugs. They say that there is still a few months to get the approval and launch of incoming medicines, so prices can change.
When will the bullets be launched?
Denmark -based Novo is expected to be approved at the end of this year and be launched immediately after that Lily in Indianapolis is expected to be launched by August 2026. Novo’s vegovi and lily’s zeepbounds (Tirjetide, type 2 diabetes and a drug used for weight loss) are given as a weekly injection. These are the only highly effective weight-loss drugs targeting GLP-1 hormone and are the largest market in the US.
In the US, their price is around ₹ 83,000 to ₹ 85,000 per month or more. Both companies provide medicines to customers paying cash in place of health insurance insurance in ₹ 41,417 to ₹ 42,415 monthly.
If we talk about India, the dosage of 1 month (4 injections) of Mounjaro in India costs around Rs 14,000 to Rs 17,500, while the dosage of 1 month of Wegovy is between Rs 17,345 to Rs 26,015.
What is more effective in injections and pills?
Both companies have said that they have developed the weight -loss drugs taken by mouth to meet the needs of patients and increase access to the market, keeping in mind that some people refrain from injections.
However, pills are not more effective than injections. Lily said this month that her bullet orfornipron lost 12.4 percent after 72 weeks in a test. At the same time, it can be compared to 15 percent weight loss from semaglutide taken daily of Novo. Both are up to 21 percent of lily injections.
UBS analyst Tung Huhinh said that the price will probably be equal to today’s existing drugs or slightly low. At the same time, TD Cowen analyst Michael Nedelkovic said that he hopes that Novo’s bullet will start around the price of Vagovi. Giving an example of the price of Ribbellasus, his diabetes pill, he said that his diabetes pill has been priced equal to the injection of Ozapics, which is the diabetic-treatment variant of Vagovi. Novo officials told analysts this month that they were not in a hurry to set a concessional price for the new bullet.
According to analysts, oral GLP-1 drugs will fill a specific place instead of replacing the injection. TD Coven estimates that by 2030, bullets will get 1 percent stake in the drug market of global obesity in mid -teenage age, which can reach about 12.45 lakh crores by then.
—- End —-